A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19

Taiga Miyazaki; Naoki Hosogaya; Yuri Fukushige; Sachiko Takemori; Shinpei Morimoto; Hiroshi Yamamoto; Makoto Hori; Yoshihito Ozawa; Yuki Shiko; Yosuke Inaba; Tomoya Kurokawa; Hideki Hanaoka; Shoya Iwanami; Kwangsu Kim; Shingo Iwami; Koichi Watashi; Ken Miyazawa; Takashi Umeyama; Satoshi Yamagoe; Yoshitsugu Miyazaki; Takaji Wakita; Makoto Sumiyoshi; Tatsuro Hirayama; Koichi Izumikawa; Katsunori Yanagihara; Hiroshi Mukae; Hitoshi Kawasuji; Yoshihiro Yamamoto; Norihito Tarumoto; Hiroshi Ishii; Hideaki Ohno; Kazuhiro Yatera; Hiroshi Kakeya; Yoshiko Kichikawa; Yasuyuki Kato; Tetsuya Matsumoto; Makoto Saito; Hiroshi Yotsuyanagi; Shigeru Kohno

doi:10.1128/spectrum.04311-22

Abstract

This is the authors' abstract. We don't add key points for this paper.

The anti-HIV drug nelfinavir suppresses the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro . However, its efficacy in patients with COVID-19 has not been studied.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Miyazaki et al. (2023) studied this question.

synapsesocial.com/papers/6aade40d13163dee1fdb8e96 https://doi.org/10.1128/spectrum.04311-22

View Full Paper

Ask AI

Bookmark

Share

A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19

Abstract

Ask about this paper

Discussion

Cite This Study

A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading